KDS-1001

N/A

Report date: 2025/04/23 11:01:29

Base Information

Drug NameKDS-1001
Drug Alias NameKDS-1001KDS1001SAR-445419
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, ChronicHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKiadis Pharma NV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiDuke University
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, ChronicHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksN/A